Adverse effects associated with clinical applications of CAR engineered T cells Journal Article

Authors: Badieyan, Z. S.; Hoseini, S. S.
Article Title: Adverse effects associated with clinical applications of CAR engineered T cells
Abstract: Cancer has been ranked as the second leading cause of death in the United States. To reduce cancer mortality, immunotherapy is gaining momentum among other therapeutic modalities, due to its impressive results in clinical trials. The genetically engineered T cells expressing chimeric antigen receptors (CARs) are emerging as a new approach in cancer immunotherapy, with the most successful outcomes in the refractory/relapse hematologic malignancies. However, the widespread clinical applications are limited by adverse effects some of which are life-threatening. Strategies to reduce the chance of side effects as well as close monitoring, rapid diagnosis and proper treatment of side effects are necessary to take the most advantages of this valuable therapy. Here we review the reported toxicities associated with CAR engineered T cells, the strategies to ameliorate the toxicity, and further techniques and designs leading to a safer CAR T-cell therapy. © 2018, L. Hirszfeld Institute of Immunology and Experimental Therapy, Wroclaw, Poland.
Keywords: immunotherapy; adverse effects; chimeric antigen receptors (cars); engineered t cells
Journal Title: Archivum Immunologiae et Therapiae Experimentalis
Volume: 66
Issue: 4
ISSN: 0004-069X
Publisher: Springer  
Date Published: 2018-08-01
Start Page: 283
End Page: 288
Language: English
DOI: 10.1007/s00005-018-0507-9
PROVIDER: scopus
PUBMED: 29427174
PMCID: PMC6879010
Notes: Review -- Export Date: 1 August 2018 -- Source: Scopus
Citation Impact
MSK Authors